We study the impact of new drug launches on early retirement due to disease and injury in the German labor force between 1988 and 2004. We show that new drug launches have substantially helped to reduce the loss of labor at the disease-level over time. In Western Germany alone, each new chemical entity is estimated to have saved on average around 200 working years in every year of the observation period. Controlling for individual determinants of retirement, the 2001 reform of pension laws appears to have led to further reductions in the loss of labor from disease and injury.
Introduction
In this paper, we study the evolution of early retirement due to disease and injury in the German labor force from 1988 through 2004 and test the hypothesis that new drug launches have helped to reduce the loss of labor at the disease level over time. Amid rapid population aging, Germany has a vital interest in extending people's productive labor force participation up to, and beyond, the current official retirement age of 65 years. Herbertsson and Orszag (2003) estimate the total cost of early retirement at around 13% of Germany's potential GDP, more than 50% above the average for all OECD countries. Rehfeld (2006) reports health-related early retirement alone accounted for 20.4 billion Euros or 2.9% of Germany's total social budget in 2003, after peaking at close to 3.5% in the late 1990s; and public pension providers paid for 60.1% of the direct costs in 2003, with most of the rest distributed among accident insurance, welfare programs for civil servants and company-based private pension providers.
Aggregate data have recorded a general decline in the number of new health-related cases of early retirement since the mid-1990s, especially among male blue-collar workers in the West and both male and female blue-collar workers in the East of Germany. In 2003, a total of 1.76 million disease and injury pensions still accounted for 7.3% of all pensions paid by Germany's public pension providers. However, the aggregate decline has masked an increasing trend towards early retirement for specific medical diagnoses, above all for psychiatric problems and-less pronounced-for neoplasms. Since the early 1980s, the average age of health-related early retirement has even dropped from around 58 years to 49 years for West-German men and from 55 years to 51 years for West-German women, whereas it has stayed roughly constant below 50 years for both sexes in Eastern Germany since 1993.
The literature has mainly attributed the general decline to changes in the relevant legal environment, such as most recently the major reform of German pension laws that came into effect in 2001 (Rehfeld 2006; Viebrok 2003) . This reform has made early retirement on medical ground less attractive financially by introducing age-adjusted replacement ratios instead of the immediate right to a full pension. However, a back-of-the-envelope calculation, based on the total number of lost employment years in 1994 and 2002 as reported in Statistisches Bundesamt (2000 Bundesamt ( , 2004 , suggests there have been substantial improvements for major diseases long before the new pension laws. While the overall disease-and injuryrelated number of lost employment years, relative to the number of employees, declined by approximately 20% between 1994 and 2002, there was a much larger decline in the case of diseases of the nervous system and the senses (more than 60%), in the case of cardiovascular diseases (45%), and in the case of diseases of the digestive system (46%). On the other hand, the reported employment loss due to psychiatric and behavioral disorders increased by more than 20%. For detailed tables, see Statistisches Bundesamt (2006) .
Our study focuses on the total amount of labor lost since 1988-the number of lost working years relative to normal retirement at 65-and thus takes into account that in terms of the economic burden, declining entry ages may compensate for a reduced number of early retirement cases. We estimate that in Western Germany alone each launch of a new chemical entity for the treatment of specific diseases has reduced the number of lost working years by around 200 working years per year, after controlling for the diagnosis according to the International Classification of Disease and Injury, ICD-9 and ICD-10, respectively, and for other factors such as age, sex, type of work, the utilization of rehabilitation services and the impact of the 2001 reform. Without the stock of new chemical entities launched in Western Germany since 1988, the total number of working years lost to disease and injury in 2004 would have been one percent higher. The total gain of working years from new chemical entities over the entire [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] period is likely to have been in the order of one tenth of the loss of labor in 2004. On the basis of average monthly disability pensions at 703 Euros for men, who accounted for approximately 70% of lost working years, and 589 Euros for women in 2003, as reported in Rehfeld (2006) , the implied financial gain to the public pension system amounts to 140 million Euros annually. The total savings from all 86 new chemical entities in the 17 year sample period is likely to have been at least ten times higher.
Methodologically, our paper builds on Lichtenberg's (2005b) health production function approach in which the age at the time of death from a given disease is regressed on the number of new drugs launched to treat the disease and on a vector of other explanatories, which may include measures of education, income, nutrition, the environment and lifestyle. We augment this framework by introducing a second equation in which for a given diagnosis and at a given age, the number of lost working years is regressed on the number of relevant drugs launched and on a vector of other variables that influence the propensity to retire. We compare the estimates from separate regressions with results from a systems approach that estimates both equations simultaneously.
Because our main focus is on the timing of early retirement, not mortality, it is useful to limit the scope of this study to one country so that changes in the relevant laws are limited to the time dimension. A cross country study would be fraught with greater difficulty in identifying the impact of new medical technology when early retirement behavior is also affected-in unknown ways-by country-specific laws. We can solve the identification problem because most new drug launches are specific to disease categories, whereas the other major explanation of changes in retirement behavior over time, observed changes in government regulation, is not.
Our identification strategy rests on the assumption that all determinants of retirement timing other than mortality are exogenous. This assumption is strictly valid only in the absence of contemporaneous or lagged dependence of disease-specific retirement hazards on the retirement hazard observed for other diseases. Even in our pseudo-panel, in which we analyze the retirement hazard for population subgroups, not individuals, the assumption may be invalid for two reasons: first, each event of early retirement from one disease may alter the composition of the population at risk of early retirement thereafter so that other diseases become a relatively more likely reason of early retirement and second, the causes underlying different diseases may be correlated. For example, when medical progress lowers the propensity to retire for cardiovascular disease, it is not surprising that age-adjusted propensities to retire for other diseases whose underlying causes are positively or negatively correlated with cardiovascular disease will change as well. Moreover, in the case of an incurable chronic disease that develops according to an exogenous probability distribution once in a person's life time, each event of early retirement will tend to lower the subsequent probability of early retirement from that cause in the retiree's cohort.
These identification issues arise from the competing risks nature of early retirement, which can be triggered by a wide range of potential health problems at the individual level. Competing risks represent both an econometric and a policy challenge. The policy challenge is to set efficient incentives for the developers of new medical technologies that reduce "early" risks and must in some way be compensated for the windfall profits they create for subsequent developers addressing "later" risks. In this paper, we begin to address the econometric challenge by developing a test for the presence of competing risks in our dataset.
The remainder of this paper is divided into six sections as follows. The "Theory" section presents the relevant theory. The "Data" section describes the data. The "Empirical methods" section presents the main empirical issues considered in the paper and motivates the choice of econometric methods that we use to identify the empirical impact of new drug launches on retirement timing with endogenous longevity. The "Estimation results" section presents the estimation results for the early retirement regression and for the regression explaining the age distribution of deaths. The "Discussion" section discusses these findings in the context of related literature. The "Concluding remarks" section concludes. 
Theory
Individual demand for early retirement is derived from a worker's demand for health. It is constrained by the trade-off between health and wealth: At what age is the expected marginal benefit from continued work, generating higher income, equal to the expected marginal benefit from retirement, helping to maintain the worker's health? As health declines, so does the relative private reward of continuing to work when pensions are available from a pay-as-you-go system. See the downward-sloping demand schedule, DD in Fig. 1 , whose location depends, inter alia, on the size of the replacement ratio of pensions to wages.
The supply curve of early retirement can be thought as a vertical line, SS in Fig. 1 , whose location is determined by the laws governing the eligibility for early retirement conditional on the applicant's state of health. For example, the major reform of Germany's disability pension system that became effective in 2001 abolished the traditional distinction between Berufsunfähigkeit, the inability to continue working in the chosen occupation, and Erwerbsunfähigkeit, the inability to work in any job. The new system distinguishes between workers still able to work between three and six hours a day, who may hence claim only a reduced pension, and those only able to work less than three hours a day, eligible to a full pension. However, the new law adjusts pension size for the age of claimants in line with the rules for early claims of old-age pensions by severely disabled persons.
It is important to note that pay-as-you-go pension funding implies a divergence between the private and social opportunity costs of early retirement when health declines. The social costs will exceed the private costs when the retiree is still in relatively good health, but the social costs will fall below the private costs when the retiree's health is very poor. The reason is that the private opportunity costs do not account for the possibility that labor productivity falls below the wage level, nor for the social insurance value of early retirement against further declines in health.
The decision making that precedes a worker's early retirement is a sequential process, in which both acute medical care and rehabilitation services may help to reduce the effective demand for early retirement. Successful acute care, in which disease-specific pharmaceutical input often plays a decisive role, produces a healthy worker who does not apply for early retirement. Rehabilitation services, by contrast, are often ordered by the pension insurer to restore a worker's health after an application for early retirement has been filed and medical eligibility has been determined; acute care has then been insufficient, yet rehabilitation services may still return a healthy worker who no longer demands to retire early. In a similar vein, the pension insurer may order retraining, termed vocational rehabilitation in the insurers' jargon, for jobs that are still compatible with the worker's health impairment.
Acute care and rehabilitation services are more likely to be substitutes for mild diseases and complements for serious diseases. Either acute care or rehabilitation may be sufficient to prevent early retirement in case of a mild disease, whereas more serious diseases require both and can still lead to early retirement. Like drugs, rehabilitation services are often diseasespecific and the extent to which the utilization of rehabilitation services and drugs should be considered substitutes or complements in the prevention of early retirement may vary across diseases. In the case of chronic diseases, rehabilitation is often accompanied by continued medication.
An important difference between the allocation of drugs and rehabilitation services is that drugs are generally available to all sick workers on equal terms, whereas rehabilitation services may not be. A pension insurer may find it profitable to target scarce rehabilitation resources at those cases where the expected savings in terms of discounted pension payments are greatest. These cases tend to be young workers, where the prospect of many future working years can justify a given rehabilitation expense even if the probability of successful rehabilitation is relatively slim.
To motivate our empirical analysis and derive testable hypotheses, let us consider a version of Philipson and Becker's (1998) model of endogenous longevity in the presence of mortality-contingent claims. A key insight of that paper is that greater longevity may stimulate private savings whenever the pension annuity is smaller than required for intertemporal consumption smoothing. However, to focus on the demand for early retirement, we shallinitially-assume exogenous longevity with a remaining life of T years. In this case, it is the earlier timing of retirement which may stimulate a demand for greater private savings, given the prospect of more years in retirement. But the shorter time that early retirees spend working means that the accumulated amount of savings available at the time of retirement may actually be lower. Consumption smoothing then implies that the annual consumption level, too, will be lower-even in the extreme case, assumed below, that the size of the pension annuity, r , is independent of the time of retirement.
For a given retirement age, the indirect utility
is obtained by perfect consumption smoothing, given wealth W , so that consumption levels are equal in every year: H (t) ) represents the functional relationship between health H , which tends to decline with age and may be subject to additional irregular disease shocks, and the marginal product of labor, which is assumed to equal wage income, with
For simplicity, we assume that r (t) is exogenous and constant for all t. If the time of retirement, R, is a variable whose value can be chosen freely, utility will be maximized by some R such that y(R) ≥ r . If y(t) > r ∀t, the utility maximizing R will be equal to T and there will be no retirement. However, we assume that health declines monotonically with time, and so does y and hence there is likely to be a timet where y t = r . The sooner H declines, the earlier will be the optimal time of retirement R for a given level of the pension annuity r . This is the basic model of the demand for retirement on health grounds. Perfect consumption smoothing requires positive savings in all periods where y (t) > r . In essence, early retirement represents a mechanism to prevent further declines in personal health. 1 Medical care, assumed to be available in fixed quantities per period, M, can be viewed as an alternative mechanism so that the relative price of medical care and early retirement will determine workers' demand for both. To account for this role of medical care, we assume that
. It follows that people will not utilize medical care as long as T − t ≥ q M, but they will consider medical care only if q M > T − t while ∂ y ∂ H ≥ pM. Intuitively, there will be some decline in health before people consider medical care as a way to halt their declining productivity. For a given effectiveness or quality of medical care, q, the demand for medical care will depend on the price p, and vice versa. We assume that new medical technology reduces p and/or increases q. However, if q is too low and/or p is too high to make the purchase of medical care worthwhile, people will want to respond to a decline in their health by going straight into early retirement. In the presence of health insurance, p is the consumer co-payment or co-insurance.
In this model, medical care serves as a substitute for early retirement. In reality, by contrast, acute medical care may-ex post-often appear to be a complement in the retiree's health production function since early retirement will rarely be granted without a prior attempt to treat and cure the applicant's disease. Public pension insurers will usually base the early retirement decision on a physical examination of the applicant's health and the prospects of restoring the applicant's ability to work. Our model does not address these details. But our empirical analysis will consider rehabilitation services as a potential substitute for early retirement, as these services are ordered by the pension insurer in an attempt to avoid incurring the early retirement liability towards the insured.
Endogenous mortality
Both early retirement and medical care, by halting the work-related decline in health, may lead to a longer life when mortality is assumed to be endogenous. This may affect the timing of early retirement, primarily through the increased demand for savings to smooth consumption over more years. A longer life expectancy may actually reduce the private incentives for early retirement and boost the demand for high-quality medical treatment so as to return to work quickly and accumulate as large a stock of savings as possible for the eventual retirement. This will raise the price of early retirement relative to medical care. Early retirement will hence happen later and demand for medical care to treat a given disease will be greater than in the case of exogenous mortality.
At the disease-level, the number of lost working years and lost life years are likely to be correlated over time-and this correlation could be either negative, since for a given state of medical technology early retirement may enhance the chances of recovering from disease or injury and of living longer, or positive, since improvements in medical technology may both reduce the need for early retirement and extend the remaining life expectancy for those receiving the best treatment. The presumption of a negative correlation follows from the health production point of view, emphasizing the-usually lagged-impact of early retirement on mortality, relative to the hazard of death in the absence of early retirement. By contrast, a positive correlation can be inferred from an investment point of view, emphasizing that a longer life expectancy may reduce the private incentives for early retirement. The positive correlation is likely to be contemporaneous if current mortality is the best predictor of future mortality from a given disease.
Competing risks
A final consideration concerns the empirical implications of the competing risk nature of retirement causes. Following Van den Berg (2005) , competing risks can be modeled as multiple durations that start at the same time for a given subject, but are only observed until the first duration is completed; it is then revealed which of the multiple durations is completed first. Both mortality and early retirement with more than one cause represent competing risks that are, however, fundamentally unidentified in empirical models (Honoré and Lleras-Muney 2006) . We therefore do not seek to quantify disease-specific hazards, but aim to provide a novel test for the relevance of competing risks for the timing of health-related retirement in our pseudo-panel.
Testable implications
We see the following testable implications emerging from the analysis:
• Early retirement for a given disease will occur less frequently and later, the more drug launches have been accumulated.
• Early retirement for all diseases will occur later, the lower the replacement ratio of pensions to wages and the more restrictive the medical eligibility criteria-implying that the legal reform coming into effect 2001 reduces the rate of early retirement.
• A decline in numbers, or an increase in the average age, of early retirement for a given disease will be accompanied by an increase of early retirement from other causes that typically occur at a later age, after controlling for the impact of new drug launches.
• A decline in the mortality from a given disease will have an additional impact on the timing of early retirement from that disease, assuming that current mortality is the best measure of expected longevity.
• Holding medical care constant, a decline in early retirement for a given disease will subsequently lead to a rise in mortality from that disease.
• Under the hypothesis of a substitutional relationship between early retirement and the consumption of rehabilitation services in the health production function, retirees who have received rehabilitation services for the main diagnosis justifying their retirement will tend to be older than those who retire without having received these rehabilitation services. To control for age as an independent determinant of the propensity to receive rehabilitation services we use observations on the rehabilitation services that retirees have received for other than their respective main diagnoses.
Data

Timing of early retirement
The dataset from the Federation of Public Pension Providers in Germany (VDR) provides detailed information on the stocks and flows in Germany's statutory pension insurance, in which more than 80% of the economically active population is enrolled. While civil servants are excluded as they are insured in the government's own tax-funded civil servant health care system, which is not covered by VDR, the statutory pension insurance is mandatory for every worker except the self-employed and those with very low earnings. In 2003, the total number of mandatory insureds was 27 million or 87% of all insureds in Germany's statutory pension insurance. The VDR gives data on new beneficiaries of disability pensions by disease, which are further differentiated by age, sex, region, type of work and a variety of other criteria. These data are grouped and available for six age intervals: 0-39, 40-44, 45-49, 50-54, 55-59 , and older than 59 years. In addition, the average age of new disability pensioners is given. Diseases are defined according to the International Classification of Disease and Injury, version ICD9 up to 1999 and ICD10 from 2000 on, as described in the data Appendix. Figure 2 illustrates the age-specificity for three major disease categories that led to early retirement in 1996 and 2003-cancer, circulatory and psychiatric diseases. While between 30 and 50% of early retirement for cancer and circulatory diseases was recorded for workers in the second oldest age group and much smaller shares in the younger age groups, early retirement was much more evenly distributed across age groups in the case of psychiatric diseases. We also calculated Kaplan-Meier estimates of survival rates, the probability of not having retired for a given disease at a certain age, for men and women as workers until their retirement on medical grounds. As a caveat, we point out that people might exit the pool of insured workers in other ways than retirement, such as death, and that measuring the efficiency in the prevention of early retirement would ideally require Kaplan-Meier estimates of survival conditional on being sick with a given disease; but we do not observe the number of diseased workers. Given these limitations, we found the highest survival rates for circulatory diseases, except for males in age intervals 55-59 and 60-64 where the highest survival rates are found for cancer and psychiatric diseases. Psychiatric problems seem to have taken a particularly heavy toll among women in the West. Survival rates are generally higher in 2003 than in 1996, especially for circulatory diseases, but appear to be slightly lower for cancer among East German males. Comparing Eastern and Western Germany, relatively small differences in cancer survival rates contrast with much larger interregional differences in survival rates for circulatory and psychiatric diseases. But whether these differences are due to differences in access to medical technology or due to temporal interdependence implied by competing risks cannot be decided unless the temporal dependence of changes in diseases-specific hazards is properly taken into account, as Honoré and Lleras Muney (2006) demonstrate in the context of mortality from cancer and cardiovascular disease.
Age distribution of deaths
By using data on the age distribution of deaths, available for the 1988-2004 period from the World Health Organization's (WHO) Mortality Database, we obtain a separate measure to control for medical technology's effectiveness at the disease level as well as an empirical handle to account for the endogeneity of retirement behavior with regard to remaining life expectancy. The distribution of deaths across age groups is therefore a potentially important variable in our empirical strategy to assess the impact of new drug launches on retirement behavior.
As a first means of comparison, we calculated Kaplan-Meier "physical" survival estimates for male and female mortality due to cancer, circulatory and psychiatric diseases in 1996 and 2003-again based on a set of six age groups, defined over five-year intervals, beginning with those below 40 years of age, but ending with an open interval of all those aged 60 or older instead of the closed interval of 60-64 year old retirement candidates. The highest risk of death is associated with cancer, although in the case of men, this risk is only slightly higher than the hazard associated with circulatory diseases. Psychiatric diseases, by contrast, appear to have the highest survival rates. Moreover, in contrast to our Kaplan-Meier estimates for retiring, the psychiatric mortality hazard, virtually unchanged over time, appears to be much less of a problem of younger workers. Cancer and circulatory disease survival rates are generally higher among females than among males, notwithstanding the evident progress between 1996 and 2003. Again, a caveat about the yet to be fully understood implications of the competing risks nature of mortality causes applies.
Drug launches
In the German health care system, access to new drugs is generally not rationed on the basis of patients' health insurance status. This is an important difference to the institutionally more heterogeneous situation in the US, where empirical studies such as Lichtenberg (2005a) find new drugs to impact societal outcomes such as ability to work with a lag of approximately 3 years. We do not think diffusion lags are as important in the Germany system, but we return to this issue in our empirical estimates in "Estimation results" section. To all enrollees of statutory sickness funds in Germany, more than 90% of the population, reimbursement of new drugs becomes available at the same time-after it has been approved by the so-called Gemeinsamer Bundesausschuss, literally the "federal joint committee," in which both the doctors' associations and the sickness funds are represented. For specific new drugs, quicker reimbursement may sometimes by available to those with full private health insurance, approximately 8% of the population. Yet, the difference in health insurance status does not result in significant differences in prescription drug access: Even enrollees of the statutory system can choose to purchase a new drug out-of-pocket that the "federal joint committee" has yet to approve for general reimbursement. While the VDR database does not actually say whether those retiring as disability pensioners have private or statutory health insurance, we assume the vast majority is in the statutory system, since only a relatively small fraction of workers with private health insurance will be enrolled in public pension insurance. Among the two major groups with a right to opt out of statutory health insurance, the self-employed will tend to choose both private health insurance and non-participation in the public pension system, whereas early retirement by civil servants, who often choose some form of private health insurance to complement the health care subsidies from their government employer, will not even be recorded in the VDR database. Against this background, we treat the time of a drug's launch on the German market as the time at which it is available to all workers at risk of health-related early retirement in our dataset. The IMS Health Drug Launches database has tracked market launches of new chemical entities (NCEs) and non-new chemical entities (non-NCEs) worldwide since 1982. When this database labels a product ingredient as a new chemical entity, these launches are guaranteed to be initial launches as explained in more detail by Lichtenberg (2005b) . It is only for products launched before 1982 that we cannot know exactly whether these contained new chemical ingredients at the time that were subsequently included in drugs launched after 1982. Following Lichtenberg, we do not count any ingredients that the database does not explicitly designate "new chemical entities" as initial launches since these might contain ingredients first launched prior to 1982. We therefore count these as non-new chemical entities, which include initial launches and re-launches. Many of these may of course be new in the sense that they possess improved pharmacological properties, such as lower side effects, but we ignore these differences among the "non-new" drug launches.
We measure the relevant stock of pharmaceutical technology for our analysis by calculating the cumulative numbers of new and non-new drug launches during three subperiods of our analysis time: first, the period before the onset of the retirement risk in our analysis, 1982-1987, second, a period in which we only consider West Germany, 1988 -1994 , and third, the period in which we consider both parts of reunified Germany, 1995 Germany, -2004 Over all therapeutic classes, we count a total 86 new chemical entity launches and 13545 non-new chemical entities between 1982 and 2004. We consider 16 therapeutic classes, such as central nervous system and parasitology drugs, with a few of the drugs applicable to more than one class. We do not attempt to assign the drugs to more detailed therapeutic subclasses because that would greatly increase the number of drugs that should be assigned to several of these subclasses. 
The linkage of drug launches to diseases Although the classification of drug launches in the IMS Health Drug Launches database and of diseases in the International Classification of Disease and Injury (ICD) follow different principles, especially at the detailed level, their hierarchical design facilitates the identification of linkages at higher levels of aggregation. At the highest level, 16 therapeutic classes correspond quite closely to 19 main disease categories in ICD9 allowing us to match 13 of these drug classes with the appropriate disease categories. For example, drug class A comprises the drugs used in the treatment of diseases bearing ICD9 codes 520-579 and drug code G comprises the drugs used in the treatment of diseases bearing ICD9 codes 580-629 and 630-676. Table 1 provides an overview of our matching between IMS drug classes and ICD9 codes and gives the total cumulative numbers of new chemical entities and non-new chemical entities for each drug class. For further details of the matching, see the Appendix.
Utilization of rehabilitation services
The great efforts Germany's public pension insurers make to prevent costly retirement by providing targeted rehabilitation services are extensively documented in the VDR database. For example, the database reveals the number of cases at the disease level where early retirement was preceded by the utilization of rehabilitation services addressing the same diagnosis that justified the retirement, and whether the rehabilitation services were provided in the last year, the last 2 years, or the last 5 years before the early retirement decision. It turns out that the number of female retirees without prior rehabilitation has declined more than the number of female retirees with prior rehabilitation, while the corresponding ratio has stayed roughly constant for male retirees since 1995. Our study exploits the more detailed information on rehabilitation input to investigate whether rehabilitation services have been effective in preventing or postponing early retirement at the disease level.
In this context, we must take into account that pension insurers ordering rehabilitation services for an applicant may not solely be motivated by medical need, regardless of age. In addition, an important motif may be the financial savings from returning a healthy worker. Concentrating a large part of scarce rehabilitation resources on young workers, where successful rehabilitation generates the largest financial savings to the pension insurer, may hence be a rational strategy. Back-of-the-envelope calculations suggest, the expected financial savings from a successful rehabilitation of a worker aged 40 may justify a five times greater rehabilitation effort, relative to the probability of success, than for a worker aged 60. Put differently, for the same annual pension payments, a rational pension insurer would try rehabilitation on a 40 year-old worker even if the probability of success were only 20 percent of that of a 60 year-old worker.
To maximize the returns from rehabilitation investments overall, the disease-specific opportunities for a successful rehabilitation will also play a role. As Fig. 3 shows, the concentration of rehabilitation services in different age groups of retirees indeed varies across diseases. In the case of cancer, 50% of early retirees aged 60 or older have received prior rehabilitation for cancer, but less than 20% of those retiring between 55 and 59, and much lower percentages of those retiring at younger ages. Moreover, the concentration among the old has increased from 1996-2003. In the case of circulatory diseases, there is a strong concentration of rehabilitation services among 55-59 year olds although it has declined from 38 to 25% between 1996 and 2003. Basically the same conclusions emerge from looking at the ratio of the number of rehabilitation services to the number of early retirees in each of the six age groups. Again, a very strong concentration of rehabilitation for cancer among the oldest workers is striking. Indeed, special rules for cancer patients require Germany's public pension insurers to consider even pensioners beyond the official maximum age of retirement as eligible for free rehabilitation services. But the picture is very different for the other five disease categories-circulatory, psychiatric, respiratory and digestive as well as diseases of the nervous system. In these cases, the ratio of rehabilitation services to the number of early retirees is much larger among the young, although the greatest relative increases in rehabilitation effort between 1996 and 2003 are recorded for the oldest workers.
In order to distinguish between the implications of differential age-related targeting of rehabilitation services from those of differential rehabilitation effectiveness at the disease level, our empirical analysis uses three different measures of rehabilitation input: first, the number of early retirees with prior rehabilitation for the retirement-inducing disease; second, the ratio of the number of early retirees with prior rehabilitation for the retirementinducing disease to the number of early retirees with prior rehabilitation for other diseases; and third, a dummy variable for retirees without any prior rehabilitation. The first of these variables is clearly inappropriate as a measure of effectiveness, since by definition the rehabilitation effort on workers who then retire has been unsuccessful. A negative impact of this variable on the loss of working years could mean that overall the rehabilitation effort has been successful or that it has been targeted mainly at older workers. Deciding which of these possibilities is correct would require observation of all successful cases of rehabilitation.
However, the VDR database does not provide the number of workers where diseasespecific rehabilitation has successfully prevented early retirement. We therefore propose using the second input variable to obtain an indirect measure of rehabilitation effectiveness. Its numerator includes only unsuccessful cases of rehabilitation whereas its denominator includes cases of rehabilitation that have presumably been largely successful for other diseases than the retirement-inducing disease, provided the diagnosis was right in the first place. Assuming that rehabilitation targeted at a specific disease has been successful in preventing some, if not all cases of potential early retirement for that disease, we should observe that on average, cases of unsuccessful rehabilitation happen at a higher age than episodes of successful rehabilitation for other diseases in the same group of workers. In essence, we are using the recipients of rehabilitation for other diseases as an instrument for the unobserved cases of successful rehabilitation for retirement-inducing disease and conclude that the targeted rehabilitation effort has been effective, on average, if the ratio defined by our second rehabilitation input variable has a significant negative impact on the loss of working years. In this case, prior rehabilitation for the retirement-inducing disease must have helped to postpone retirement relative to prior rehabilitation that the same group of workers received for other diseases.
Finally, a positive impact of the third rehabilitation input variable, the dummy for those without any rehabilitation prior to their health-related retirement, on the loss of working years would reinforce the conclusion that rehabilitation is generally effective in preventing or postponing early retirement on medical grounds.
Empirical methods
Econometric framework
Our data represents a pseudo panel and allows us to apply a variety of panel data methods. The presumed endogeneity of early retirement with respect to remaining life expectancy at the disease-level can be captured by a two-equation model-including an early retirement and a separate mortality equation. In addition, dynamic panel methods may be required because each case of deferral of retirement this year, for example because the public pension insurer wants to try rehabilitation first, may affect the probability of early retirement next year and this would introduce exactly the sort of autocorrelation structure that dynamic panel methods are designed to address.
The early retirement equation
We hypothesize that the number of lost working years from disease i in year t (R it ) depends on the cumulative number of new chemical entities launched (Cum_NC E it ) and the cumulative number of non-new chemical entities launched (Cum_non − NC E it ) to treat disease i by time t, and other factors (X it ) that may affect the number of early retirees and the timing of retirement:
We define
with α i = a fixed disease effect which is invariant across years in disease i, λ ji = a fixed effect for disease i in educational background, blue-collar workers ( j = 1), white-collar workers ( j = 2) and miners ( j = 0), respectively, ω i = a fixed effect for disease i in men (1) and women (0), respectively, ξ i = a fixed effect for disease i in Eastern (1) and Western Germany (0), respectively, θ t = a fixed year effect which is invariant across diseases in year t, and Y jit = the number of early retirees in disease i who received rehabilitation services for disease i ( j = 1) and the number of early retirees in disease i who received rehabilitation services for other diseases ( j = 2), and Z jit a vector of mortality from disease i ( j = 1) and from other causes ( j = 2) at various age intervals. Substituting (2) into (1) yields
where
and the standard error term
This functional form is linear in the stocks of new drugs for two reasons: First, taking logarithms, as Lichtenberg (2005a) does, would make estimation with our preferred methods difficult for disease categories that have no new drug launches in some years. Second, given the relatively small numbers of NCEs, we do not believe that medical care is already running into diminishing returns, the usual economic justification for taking logarithms. Instead, we see the adoption of new drugs as an investment that often leads to new treatment guidelines and protocols in medical practice and involves adjustments in other inputs which we do not measure. We think appropriate adjustments in medical practice may imply non-diminishing returns to NCEs for the many diseases where unabated streams of improvements in treatment outcomes have been observed during the relatively long sample period of our study. Lichtenberg (2005a) provides a more detailed discussion of how the omission of unmeasured medical innovations may affect the interpretation of the estimated impact of new drugs in our type of empirical study. Moreover, some of our explanatories can be interpreted aspartial-controls for disease prevalence, so that we have confidence in the linear model also from the cross-sectional perspective.
The mortality equation
We employ a second equation which is similar to Lichtenberg's (2005b) regression for the impact of new drug launches on the loss of life:
where L it is the number of lost life years relative to 100 from disease i in year t, X * it is a vector of factors that may affect mortality from disease i and Z * jit a vector of lost working years from disease i ( j = 1) and from other diseases ( j = 2) at various age intervals.
withα i = a fixed disease effect which is invariant across years in disease i,ω i = a fixed effect for disease i in men (1) and women (0), respectively. Substituting (5) into (4) yields
whereα i = δα i ,ω i = δω i ,θ t = δθ t , and the standard error termũ it = δν it +ε it .
Estimation methods
We begin by estimating the early retirement and the mortality equations separately, using the random-effects generalized least squares method (henceforth random effects GLS) to estimate a static model. In many situations, the random effects GLS is an efficient estimator because it exploits both within and between group variations to obtain a weighted average of fixed and between effects for time-invariant variables such as disease, sex, educational background, and the region on lost working years in the early retirement equation. We use the static model to examine the relevance of diffusion lags in the impact of new drugs-by comparing estimates with a 3-year lag in the stocks of new drugs and estimates without such a lag. However, our aim is to estimate not only the early retirement equation for lost working years but also the mortality equation for lost life years, and to account for the endogeneity of lost life years with respect to lost working years, and vice versa. This is not feasible with the random effects GLS. Assuming the lost working year variable is not strictly exogenous in the equation for lost life years, and vice versa, correlations between the explanatory variables and the error terms will occur. The random effects GLS estimator will then yield biased and inconsistent results. To overcome these problems, we require a panel data simultaneous equation model that takes the relationship between the equation for lost working years and the equation for lost life years. We therefore propose to employ a two-stage least squares (2SLS) model, namely the error component two-stage least squares (EC2SLS) model, which deals with the endogeneity problem by means of instrumental variables to produce consistent estimators.
We prefer EC2SLS in the static model because the presence of error components renders simpler 2SLS estimators asymptotically inefficient, whereas EC2SLS is derived as an asymptotically efficient and consistent estimator under fairly general assumptions. We perform the estimation using Baltagi's (1981) EC2SLS estimator, which improves upon the earlier Balestra and Varadharajan-Krishnakumar 2SLS estimator by using a broader set of transformations of the instruments spanning those used by the latter estimator. Because the instrumental variables must be correlated with the suspect explanatory variable, but uncorrelated with the error term, we use the variables on the right-hand side in the mortality equation as instrumental variables for the endogenous regressor of lost life years in the early retirement equation.
However, while EC2SLS leads to consistent estimates if the underlying assumptions are satisfied, it is not necessarily the most efficient estimator in our context because it does not make use of all available moment conditions, nor does it take into account the differenced structure of the residual disturbances (Ahn and Schmidt 1995) . It may even be biased when lagged dependent variables are included as regressors in both the early retirement and mortality equations. We therefore also employ a dynamic panel model, in which we account for the dynamic dependence structure that could otherwise lead to biased estimates.
To estimate the dynamic panel model, we use the generalized method of moments (GMM) proposed by Arellano and Bond (1991) . In the early retirement equation, GMM corrects for the endogeneity of the lost-life-years variable, and for the potential bias introduced by the lagged lost-working-years variable in the presence of fixed effects. Likewise, in the mortality equation, GMM corrects for the endogeneity of the lost working year variable, and for the bias introduced by the lagged lost-life-years variable in the presence of fixed effects. The use of instrumental variables allows parameters to be estimated consistently in the model, which includes endogenous right-hand side variables such as the lost life year variable in the early retirement equation. Moreover, the GMM estimator will no longer be biased by any omitted variables that are constant over time. We estimate both the one-step GMM estimator and the two-step GMM estimator for the dynamic panel to verify that the signs of coefficients are consistent. However, we do not report the two-step GMM results, because Arellano and Bond recommend using one-step results for inference on the size of the coefficients.
While GMM has many important advantages, it may suffer from a few drawbacks of its own. For example, biases can occur when instrumental variables are weak. In particular, when the number of time series observations is small, the GMM method is often poorly behaved; under the relevant moment conditions, lagged levels of the endogenous regressors may be weak instruments for the subsequent first-differences. Because we want to avoid basing our inference on estimation results that are specific to one method only, we use all three methods in parallel, the random effects GLS and EC2SLS methods in the static model and GMM in the dynamic model. We evaluate specification tests to determine the merits of each method for our purposes.
Testing for competing risks
Another potentially relevant source of inter-temporal interdependence is the competing risks nature of diseases as causes of early retirement. New drugs that help to prevent early retirement from one disease may give other diseases for which effective drugs have not yet been introduced the opportunity to become a more significant factor in early retirement, although typically at a higher average age of the retirees. Testing for the presence of competing risks is complicated by the fact that we do not track individuals over time, but only observe hazard rates of early retirement for groups of workers at various levels of aggregation. Even if competing risks are relevant at the individual level, they may play little or no role at higher levels of group-wise aggregation.
To design a test at the level of aggregation used in our empirical analysis of retirement determinants, we re-arrange the data and create three non-overlapping five-year time intervals during which we can observe cohorts of workers at risk as they grow old: 1988-1992; 1993-1997; and 1998-2002 . While we cannot be sure that all workers under 40 years of age will be in the next age group, 40-44 years of age, 5 years later, this is guaranteed to be the case for all workers at risk of early retirement in any of the four age groups between 40 and 59-namely 40-44 years, 45-49 years, 50-54 years, and 55-59 years of age-since each of these spans 5 years and is followed by another five-year interval in which the same cohort of workers will still be at risk of early retirement. Only workers in the 60-64 age group will not be at risk of early retirement 5 years later, since they will have passed the maximum retirement age and will hence already be retired.
There are only three cohorts of workers that are at risk of early retirement in all three time intervals. The first of these cohorts, aged 40-44 in the first time interval, will be in the 45-49 age group in the second time interval and in the 50-54 age group in the third time interval. The second cohort, aged 45-49 in the first time interval, will be in the 50-54 age group in the second time interval and in the 55-59 age group in the third time interval. The third cohort, aged 50-54 in the first time interval, will be in the 55-59 age group in the second time interval and in the 60-64 age group in the third time interval.
We define as the fourth and fifth cohorts those that are observed over two time intervals. The fourth cohort comprises workers who are in the 55-59 age group in the first time interval and in the 60-64 age group in the second time interval. The fifth cohort comprises workers who are in the 40-44 age group in the second time interval and in the 45-49 age group in the third time interval. Finally, we define as the sixth cohort workers aged 40-44 in the third time interval and as the seventh cohort workers aged 60-64 in the first time interval; these two cohorts are hence only observed once in the re-arranged dataset.
Figures 4 and 5 display the changing retirement hazards in time intervals two and three, differentiated by the five-year age groups and disease classes, for male and female workers, respectively. These hazards rates are plotted on the vertical axis whereas the horizontal axis shows the original hazard rate in the first time interval. This captures the idea that "later" hazard rates depend on "earlier" hazard rates. It is immediately apparent that virtually all dots in both graphs lie below the imaginary diagonal for equal hazard rates, confirming the rather general hypothesis that there have been significant reductions in the retirement hazard over time.
Furthermore, the Figs. 4 and 5 give us detailed insight into changing hazard rates at the level of diseases for specific age groups and cohorts of workers at risk of early retirement. Each dot in the graph is accompanied by a six-digit number starting in the first digit with number 2 or 3 to indicate the time interval of the hazard rate on the vertical axis, followed by two digits to indicate the lower bound of the age group and by three further digits to indicate the disease class. For example, the highest hazard rate on the vertical axis, at around .021, is observed in time interval 2 for male workers aged 60-64 suffering from musculoskeletal diseases (class 710-739). But in the first time interval, plotted on the horizontal axis, the corresponding hazard rate for musculoskeletal diseases among male workers aged 60-64 is even higher, at .025. In the third time interval, finally, the corresponding hazard rate has dropped to .01, more than 50 percent lower than in the preceding time interval.
The graphs also allow us to follow changing hazard rates within cohorts as they age. For example, the same cohort that experienced a hazard rate of early retirement of .01 due to musculoskeletal diseases when aged 60-64 had a hazard rate of close to .015 5 years earlier when these workers were aged 55-59 years. This age group in turn had an original hazard rate, in the first time interval, of around .018 and a hazard rate of .009 in the third time interval. The graphical display of cohort-specific hazard rates thus suggests that changes observed within cohorts as they age can be decomposed into a time effect, which may be due to medical progress and/or legal changes, and a cohort-specific aging effect, which may be due to the age-specificity of diseases and the competing risks nature of diseases as retirement hazards.
In Figs. 4 and 5, only a small group of major diseases, above all musculoskeletal, circulatory and-in the case of women-psychiatric diseases, represent relatively large hazards of early retirement and these diseases' hazard rates are at their peak in the age group 55-59. But even these appear to decline with time when the age group is held constant. Most diseases are associated with much lower hazard rates of early retirement, although together they may create a significant part of the overall disease-induced retirement hazard in younger age groups.
In Table 2 , we first report results of the Wilcoxon signed-rank test and the sign test of whether changes in the age group-specific hazard rates observed between consecutive fiveyear time windows are significantly different from zero. We find they are, except for the changes in hazard rates in the 40-44 and 45-49 age groups. However, the last two columns show that the two changes for each age group across the three time windows in our dataset are generally not significantly different from each other in the case of male workers, but in most age groups they are in the case of female workers.
Summing up, we conclude there is no real evidence to support the hypothesis that competing risks are a significant factor at the level of aggregation across diseases and age groups that characterizes our study. We reach this conclusion not because we do not see a great deal original hazard Fig. 4 The decline of retirement hazards for men, by age and disease of variation in the disease-specific retirement hazards across time, age groups and cohorts in our dataset. We document substantial evidence of such variation. However, the only major disease category that appears to have a robust impact on subsequent retirement hazards for other diseases is circulatory diseases, which have seen a steady decline as a retirement original hazard Fig. 5 The decline of retirement hazards for women, by age and disease hazard for both men and women since the early 1980s. Based on our test results, we go on to investigate the empirical impact of new drug launches on retirement hazards without further consideration of the competing risks hypothesis. Changes from 1988 -1992 to 1993 -1997 Changes from 1993 -1997 to 1998 -2002 Male Test for differences in changes of agegroup-specific hazard rates between 1988-1992 and 1993-1997 and 1993-1997 to 1998-2002 
Estimation results
We begin by reporting estimates of the early retirement equation for Western Germany over two periods of time-the entire sample period from 1988 to 2004 and the subperiod from 1992 to 2004. We run separate regressions for the subperiod because more detailed data on the allocation of rehabilitation services at the disease level is available in this case. For the entire period, only the aggregate number of early retirees with prior rehabilitation for all age groups is available at the disease level. For the subperiod, we have more detailed information, such as separate information on the number of early retirees with prior rehabilitation for the retirement-inducing disease and for other diseases than the retirement-inducing disease. The retirement-inducing disease might also be called "rehabilitation-resistant" since the dataset only includes actual cases of early retirement so that all rehabilitation effort spent on the disease on which the claim is based must have failed in preventing the loss of that particular worker. By contrast, prior rehabilitation efforts for other diseases might have been successful, unless they were based on a false medical diagnosis; in this case they would have been merely superfluous. Table 3 reports the results of all three econometric models discussed in the preceding section: first, random-effects generalized least squares regressions (reGLS); second, the error component two-stage least squares estimation (EC2SLS); and third, the ArellanoBond dynamic panel data estimation (GMM) for the early retirement in Western Germany from 1988 to 2004. Columns 1 and 2 of Table 3 report random-effects GLS early retirement regressions, first with a 3-year lag in the stocks of new drugs and then without a lag. We include among the explanatory variables two new variables-the cumulative number of lost life years for the retirement-specific and for other diseases; the cumulative number of lost life years is determined by adding the number of lost life years in the retiree's age group and in all higher age groups, thus comprising all age groups in which that worker might be affected by mortality from the retirement-inducing or from other diseases. In this way, our regressions control for changes in remaining life expectancy at the disease level, in line with the derivation of the demand for early retirement from the trade-off between life-cycle wealth and health.
All regressors turn out to be statistically significant. The cumulative number of new chemical entities has a negative coefficient of-137 when it is lagged by 3 years and an even larger negative coefficient of-220 when it is unlagged: The greater the available stock of NCEs to treat a given disease, the smaller the number of lost working years attributed to that disease. Because the estimation with lagged regressors has less explanatory power and yields coefficient estimates with the same signs and mostly similar magnitudes, but larger standard errors, we continue with the unlagged model only. 2 The stock of non-NCEs therein has a significant positive coefficient, but the impact of the average drug in this category appears to be very small, compared with the average NCE. Similarly, we find the cumulative numbers of lost life years to have highly significant negative coefficients that are close to zero. Using the number of early retirees with rehabilitation, we estimate a positive coefficient for the impact of rehabilitation-a puzzle to be investigated further. The results in the first column show larger losses of working years for blue-collar, male and younger workers, and a much smaller loss for miners. Finally, the legal reform coming into effect at the beginning of 2001 is estimated to have reduced the loss of labor by 524 working years in every subsequent year.
Column 3 of Table 3 reports the results of EC2SLS regressions, without lags. This model yields results that are virtually the same in terms of coefficient signs and very similar in terms of coefficient magnitudes when compared with the corresponding regressors in column 2.
Column 4 of Table 3 reports one-step results of our dynamic panel data model estimated with GMM. We use the one-year lagged number of lost working years as an endogenous regressor and see that its coefficient is almost 1.0 and highly significant. This regression thus reveals substantial persistence in health-related retirement behavior at the disease level, which is not captured by the other variables. New chemical entities still have a negative impact and a similar coefficient magnitude in the dynamic panel model, but the other variables change their sign or coefficient size. For example, the dummy variable for the legal reforms coming into effect at the beginning of 2001 is now estimated to have a positive impact on the number of lost working years. If true, this would mean that the reforms had the unintended and perverse effect of increasing the burden of early retirement. However, this particular result is likely to be biased because by using first differences of all variables, the GMM fails to take into account that the reforms are not withdrawn at the end of 2001, but remain in force in all subsequent years. Note that the other dummy variables-for male, blue-collar workers and miners-have been dropped altogether because they are time-invariant and first differences of these are always zero. Table 4 reports the results of our early retirement regressions for Western Germany from 1992 to 2004, the period for which we have more detailed information-differentiated by age group at the disease level-on the number of early retirees with prior rehabilitation for the main retirement-inducing diseases and on those with prior rehabilitation for other diseases.
To capture the impact of rehabilitation efforts on early retirement in line with the testable implications of our theoretical considerations, we include three different rehabilitation variables in each of these regressions: first, the number of early retirees with prior rehabilitation for the main retirement-inducing disease, second, the ratio of the number of early retirees with prior rehabilitation for the main retirement-inducing disease to the number of early retirees with prior rehabilitation for other diseases, and third, a dummy variable for early retirees without any rehabilitation input. Columns 1 and 2 of Table 4 report results of random-effects GLS regressions, again first with a 3-year lag in the stocks of new drugs and then without a lag. Again, the coefficient estimates for the unlagged NCEs and non-NCEs have larger size and smaller standard errors and we continue with the unlagged model in column 2. For the main variables of interest, the estimated coefficients are similar to the ones reported in columns 2 and 3 of Table 3 . Our main interest in Table 4 is to better understand the impact of rehabilitation services, ordered by the pension insurer, on the loss of labor from disease and injury. We first note that the dummy variable for no rehabilitation is insignificant in column 2. As in Table 3 , the impact of prior rehabilitation for the main retirement-inducing disease is estimated to be significant and positive. However, this model shows a significant negative impact of the ratio of the number of early retirees with prior rehabilitation for the main retirement-inducing disease to the number of early retirees with prior rehabilitation for other diseases. Thus, increasing the rehabilitation effort targeted at the main retirement-inducing disease relative to the rehabilitation effort for other diseases appears to result in at least some prevention of retirement for the targeted disease. The negative coefficient for the ratio suggests that early retirees with prior rehabilitation for the main retirement-inducing diagnosis tend to retire later than early retirees with prior rehabilitation for other diseases. This in turn tends to reduce the number of lost working years.
Column 3 of Table 4 reports the results of EC2SLS, taking into account the potential endogeneity of the explanatory variable lost life years, and largely confirms the findings of column 2. The positive coefficient on the no rehabilitation dummy underlines the conclusion from our interpretation of column 2 that targeted rehabilitation is effective in preventing or delaying health-related early retirement, albeit statistically insignificant.
Column 4 of Table 4 reports the results of a dynamic panel model estimated with GMM. As we cannot reject the specification tests, we conclude that the model yields consistent estimates. The first lag of the number of lost working years is highly significant and close to one, as in the model with longer time series reported in column 4 of Table 3 . Most other variables of interest also have the expected sign. Even the impact of Germany's pension law reforms coming into effect at the beginning of 2001 is now estimated as strongly negative. However, the ratio of the number of early retirees with prior rehabilitation for the main retirementinducing disease to the number of early retirees with prior rehabilitation for other diseases is no longer significant. Also the dummy variable for early retirees without prior rehabilitation is insignificant.
In the working paper version of this article, we also report estimates of the early retirement equation for total Germany, comprising both Eastern and Western Germany, but due to limited data availability in the East, only for the subperiod from 1995 to 2004. The signs and magnitudes of the estimated coefficients are similar to our previous estimates, except for the coefficient on the stock of new chemical entities. With a parameter value below 100, the estimated impact appears to be only half as large as in the regressions for Western Germany. The dummy variable for no rehabilitation is estimated as highly significant and positive, confirming the effectiveness of rehabilitation in preventing or delaying health-related early retirement. A dummy variable that controls for residence in Eastern Germany yields a significant negative coefficient.
Applying the GMM method to the dataset for total Germany from 1995 to 2004, we also estimate mortality dynamics at the disease level. The results show that both the stock of new chemical entities and the stock of non-new chemical entities have helped to lower the number of lost life years at the disease level. However, the coefficient for lost working years is insignificant. The legal reform coming into effect at the beginning of 2001 is estimated to have a significant positive impact on mortality. But that such an effect should be detectable so soon after the reform calls for closer empirical scrutiny, which is beyond the present paper.
Discussion
In this paper, we have used alternative econometric approaches to study the impact of new drug launches on the loss of labor from disease and injury over time. By including a second equation for the impact of new drug launches on mortality and by including changes in mortality in the set of explanatory variables of the first equation, the equation for the loss of labor, we have allowed the choice of early retirement and the savings motive for old age to be interdependent, as implied by economic theory. Although the mortality measures are statistically significant in the early retirement equation and the loss of working years is statistically insignificant in the mortality equation, the size of the estimated coefficients is close to zero.
We find that regardless of econometric method, the negative impact of new chemical entities on the number of lost working years at the disease level is robust and sizable. In regressions for Western Germany alone, each new drug incorporating new chemical entities saves around 200 working years in every year that it is on the market. The corresponding coefficient for total Germany is also highly significant and has the same sign, yet only about half the absolute size.
The finding of a lower impact of new chemical entities in total Germany, compared with Western Germany alone, may reflect delayed diffusion of new drugs in Eastern Germany, which in turn might be caused by a more conservative prescribing behavior and by a lower density of medical practitioners in that region, with implications for the frequency of patient contacts, the timing of treatment initiation in case of illness and subsequent compliance. An additional factor might have been the mass restructuring of former East German industries in the early 1990s in which many less healthy workers joined the ranks of the long-term unemployed and thus ceased to be candidates for early retirement on medical grounds. Remember that our dataset for total Germany begins only in 1995, when much of the industrial restructuring had already been completed.
It was beyond the scope of this study to further investigate the relative importance of these explanations for the lower impact that new chemical entities appear to have had on retirement behavior in Eastern Germany. However, we believe that regressions using the longer time series of observations we have for Western Germany more likely reveal the true impact of new chemical entities on the loss of labor from disease and injury over time.
In both total and Western Germany, the impact of non-new chemical entities is less clear; although statistically significant in our regressions, the estimated coefficient is too small to attribute much economic significance to the stock of non-new chemical entities in our explanation of the hazard of early retirement at the disease level.
In addition to medical technology, our study considers the utilization of health services, in the form of rehabilitation services ordered by Germany's public pension providers to prevent the loss of labor associated with early retirement. We find evidence that targeted rehabilitation has been effective at the disease level in the sense that it either prevents or delays early retirement, relative to the average age at which workers retire from a given disease without the rehabilitation effort. This conclusion is also supported by the observation that the absence of rehabilitation effort tends to increase the loss of labor at the disease level.
However, these conclusions are tentative for three reasons: first, we only observe retiring workers, where by definition, rehabilitation targeted at the retirement-inducing disease has ultimately been unsuccessful from the public pension provider's point of view. Second, our data does not reveal the extent of rehabilitation effort for individual workers, but only at the level of groups of workers retiring for a given disease. And third, an explicit theoretical model that explains the allocation of scarce rehabilitation resources across diseases and across age groups is not available. It is unlikely that medical opportunity alone determines this allocation; instead, a pension provider may find it profitable to target rehabilitation primarily at workers where large savings in disability pension payments may be obtained even if the medical prospects for successful rehabilitation are relatively poor.
More research would be desirable to better understand the impact of rehabilitation services on early retirement. Such research should, inter alia, seek to understand the interdependence of medical rehabilitation and retraining, referred to as vocational rehabilitation by Germany's public pension providers. It would be desirable to derive testable implications from an explicit model of optimization that explains the determinants of resource allocation in the effort to restore workers health and return them to suitable jobs. To provide additional insights, future empirical research should be based on more detailed knowledge at the disease level about the specific medical opportunities for successful rehabilitation. Such knowledge would also help to understand the relationship between rehabilitation and medical technology: for example, to what extent is new medical technology, such as new drug launches, a substitute or a complement to rehabilitation services in preventing early retirement?
Some recent studies focus on individual diseases that avoid some of the limitations of large cross-section or panel data studies, such as ours. For example, Conti et al. (2006) investigate the impact of depression on the labor force participation of elderly workers in the US and find evidence of direct and indirect effects on workers' propensity for early retirement. Ignoring the indirect effects would lead to an underestimation of the impact of depression and a potential overestimation of the impact of other diseases or life events, such as widowhood, with which depression often interacts. This finding is related to the problem of competing risks that we found difficult to identify at the level of aggregation across disease categories that characterizes our study. Knowledge about specific interaction effects between diseases and between different medical treatment technologies would surely help to identify complementarities and competing risks in cross-section and panel studies.
In a second recent study of disease-specific disability retirement, Cutler et al. (2008) explore the role of improved medical treatment for cardiovascular disease in explaining the observed decline in disability for more than two decades in the US. Specific pharmaceutical product innovations appear to explain more than 50 percent of the observed reductions in disability and deaths over time, controlling for the utilization of other types of medical care inputs, such as hospitalizations.
Within the framework of cross-section and panel studies, a promising strategy to better distinguish the role of medical technology from other determinants of health and labor force participation may be to include more than one country. Institutional differences in countries' health systems, pension laws and labor markets as well as differences in access to medical technology provide natural experiments that are waiting to be evaluated. Kalwij and Vermeulen (2005) already study the impact of multi-dimensional measures of health on the elderly's labor force participation in a cross-section of 11 European countries based on the Survey of Health, Aging and Retirement in Europe (SHARE). They find substantial differences in the importance of different attributes of health across countries. But these authors do not consider the role of medical technology.
International panel studies may also provide an opportunity to better understand the problem of competing risks in determinants of early retirement and death due to disease and injury. It is difficult to identify competing risks models in the absence of counterfactual observations; see Honoré and Lleras Muney (2006) for the methodological state-of-the-art in the estimation of competing risks when their observability is interdependent due to endogenous censoring in a given set of subjects at risk. Different institutional and epidemiological conditions as well as differential access to medical technology across countries might help to identify competing risks in appropriate multinational panel studies in the future. This would not only be desirable because we could then avoid overestimating the impact of the "earlier" medical technology innovations and underestimating the impact of "later" innovations. It might also help to identify the type of medical technologies where the competing risks problems are likely to create significant disincentives and coordination problems for investors. 3 However, to fully understand the role of medical technology, we will also need new contributions from economic theory: First, on the relationship between early retirement and endogenous longevity, which matters because medical innovation may have direct and indirect effects on the propensity for early retirement. The direct effect stems from better medical treatment that helps to maintain or even improve people's health, and labor productivity, whereas the indirect effect results from changes in the private incentives for early retirement. On the one hand, a longer life expectancy and the prospect of a higher quality of life may increase the demand for private savings and may hence increase people's labor force participation. On the other hand, people may want to enjoy some of their improved health by increasing their consumption of leisure.
Secondly, economic theory should address the relationship between the demand for early retirement and the demand for medical care and should provide a testable health production function that encompasses potential complementarities, such as the relationship between acute care and early retirement, and potentially substitutional relationships, such as that between early retirement and the utilization of rehabilitation services. On this basis, the role of innovations in medical technology in changing the relevant trade-offs and constraints in the production and maintenance of health over the life cycle could be investigated in much greater detail.
Concluding remarks
In this paper, we have explored the evolution of early retirement due to disease and injury in the German labor force between 1988 and 2004, combining for the first time three relevant datasets: the disability retirement records from the German Federation of Public Pension Providers, the IMS Health Drug Launches database and the WHO Mortality Database. Using a variety of econometric methods to exploit the pseudo-panel structure of the combined dataset, we find that in Western Germany alone each new chemical entity has on average saved around 200 working years in every year. Controlling for individual determinants of health-related retirement, such as workers' age, sex and type of work, we also find evidence that the 2001 reform of pension laws has led to further reductions in the loss of labor from disease and injury.
In addition, we use non-parametric tests and regression analysis to investigate the relevance of the competing risks hypothesis in the empirical determinants of early retirement at the disease level. We argue that the presence of competing risks in individual retirement behavior is unlikely to affect the conclusions suggested by our empirical estimates of the impact of new drug launches on retirement timing in Germany. We therefore conclude that our findings provide a first estimate of an important part of the social gains from reductions in early retirement that were brought about by new pharmaceutical products in Germany between 1988 and 2004. The total welfare gains are likely to be substantially larger as they must include an aggregate measure of workers' willingness-to-pay for potential health benefits and the gain in lifetime personal income that voluntary deferral of retirement affords. Nonetheless, we believe our findings could help to assess the extent to which Germany, and other OECD countries, might want to raise the official maximum retirement age and change eligibility criteria for health-related early retirement in response, or anticipation, to future progress in medical technology.
the Anatomical Classification of Pharmaceutical Products that has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is the intellectual property of this association. The classification is very detailed, with more than 500 therapeutic classifications (A1A1-V3X9) at the most detailed level, such as mouth antiseptics and anti-infectives (A1A2). At the highest level, there are 16 categories (A-V), e.g. alimentary tract and metabolism (A). Each record gives the date of product launch, the active ingredients, the therapeutic class and the name of the responsible corporation. Because Germany was separated into East and West before 1990, the IMS data have two categories, named Germany and West Germany. Data on drug launches in the West Germany category are available from 1982 to 1992, in the Germany category from 1985 to 2004. To get the number of new drug launches in total Germany from 1982 to 2004, we add the number of new drug launches in the two categories, taking care that new drug launches are not counted twice if they appear in both the West Germany and Germany categories during [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] .
The International Classification of Diseases and Related Health Problems (ICD) is under the responsibility of the World Health Organization (WHO). In German disability retirement, the 10th revision (ICD-10) came into use as from 2000, replacing the 9th revision (ICD-9). This change makes it necessary to use a concordance for the disease categories between ICD-9 and ICD-10 that are relevant to our study and match the observations in accordance with one of the classification schemes for the entire 1988-2004 period. The ICD-9 contains 19 so-called chapters, i.e. disease categories on a highly aggregate level, whereas ICD-10 contains 21 chapters. We performed the matching between the two classifications on the basis of 19 ICD-10 chapters. Matching on a more disaggregate level would have been more difficult as there are 1182 three-character categories in ICD-9, while there are 2036 three-character categories in ICD-10. Many disaggregate disease categories do not match one-to-one, but matching on the level of the 19 main disease categories can be performed with a relatively high accuracy.
